CD8A and neoplasm: Recent work with engineered IL-4 variants suggests that selective modulation of IL-4 signaling could revitalize exhausted CD8+ T cells, providing new opportunities to enhance anti-tumor immunity while minimizing the immunosuppressive effects of the cytokine [26].